Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | DGKA | P23743 | 1/20 | 0.35 |
| ▸ | PPM1B | O75688 | 2/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.34 |
| ▸ | PPP1CC | P36873 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20185591 | 0.81 | ALDH1A1 (0.34) | NLRP3ALDH1A1LMNA | |
| SCHEMBL20185594 | 0.79 | ALDH1A1 (0.43) | ALDH1A1LMNAPOLBEPHX2 | |
| SCHEMBL28992210 | 0.74 | LMNA (0.54) | ALDH1A1LMNAPOLB | |
| SCHEMBL1842580 | 0.74 | DGKA (0.41) | NLRP3DGKAPPM1BPTPN1PPP1CC | |
| SCHEMBL28992186 | 0.73 | NAAA (0.39) | NLRP3DGKAPPM1BPTPN1PPP1CC | |
| SCHEMBL18269637 | 0.73 | LMNA (0.42) | ALDH1A1LMNAPOLB | |
| SCHEMBL29266732 | 0.73 | EPHX1 (0.54) | DGKALMNAPOLBEPHX2 | |
| SCHEMBL28992214 | 0.73 | LMNA (0.49) | ALDH1A1LMNAPOLBEPHX2 | |
| SCHEMBL18269659 | 0.73 | LMNA (0.42) | ALDH1A1LMNAPOLB | |
| SCHEMBL10202271 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10618898-B2 | Hydroxyl purine compounds and use thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2020-04-14 | — | — | US | disclosed |
| US-20180148451-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148451-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | PNP, PDE7A, PDE2A | NLRP3 305/4885DGKA 1814/4885PPM1B 334/4885 |
| US-10618898-B2 | Hydroxyl purine compounds and use thereof | PNP, PDE7A, PDE2A | NLRP3 305/4885DGKA 1814/4885PPM1B 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.